Pharmafile Logo
Pharmafocus logo
Advanced Search

Addenbrooke’s hospital offers first self-service digital eye test

July 17, 2025
Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology

Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system – DigiVis DVA system …

News
trial

Biogen and Stoke report positive results for Dravet syndrome drug

July 17, 2025
Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …

News
Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

July 16, 2025
Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …

News

Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth

July 16, 2025
Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience

Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …

Appointment

Osivax publishes positive results from trial of influenza vaccine candidate

July 15, 2025
Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases

French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …

News
clinical_trial-web

Pharvaris to report phase 3 data and submit New Drug Application

July 15, 2025
Medical Communications, Research and Development Pharvaris, Rare Diseases, US Food and Drug Administration, clinical trial, genetic condition, new drug application

Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of …

News
nerve-cell-2213009_960_720

Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders

July 14, 2025
Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions

Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …

News
money_pills_2

VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium

July 14, 2025
Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics

VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …

News

Cube Biotech appoints Joachim Kreuzburg to its board of directors

July 11, 2025
Research and Development Corporate, Cube Biotech, IBA Life Sciences, Sartorius, archimed, board of directors, membrane protein production

German-based Cube Biotech announced the appointment of Joachim Kreuzburg to its board of directors. This will support the development of …

Appointment
bowel_cancer_screening

NICE recommends NHS use of mirikizumab for Crohn’s disease

July 11, 2025
Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial

Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …

News

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design

July 11, 2025
Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology

BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …

News

Norstella appoints Kris Joshi as CEO to drive next phase of growth

July 10, 2025
Business Services, Consultancy CEO, Corporate, HealthTech, Norstella

Pharma intelligence solutions provider, Norstella, has appointed health-tech leader, Kris Joshi, as its new chief executive officer (CEO) with former …

Appointment

Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes

July 10, 2025
Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases

Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …

News

Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani

July 10, 2025
Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology

Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …

News
Mosquito image

First malaria medicine for infants under 4.5kg receives approval

July 9, 2025
Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …

News
Patients image

First adult in the UK given new treatment for type 1 diabetes

July 9, 2025

The first adult in the UK to trial Tepilzumab for type 1 diabetes has started treatment at the Royal Devon …

News

Richard Philipson appointed as chief medical officer of Hansa Biopharma

July 9, 2025
Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …

Appointment
money-2180330_960_720

Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy

July 9, 2025
Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes

French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …

News
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025
Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …

News
senior-woman-suffering-from-knee-pain-home_61573-2004

SMC recommends Eladynos for postmenopausal osteoporosis in Scotland

July 8, 2025
Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause

Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025